{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:02:20Z","timestamp":1781222540771,"version":"3.54.1"},"reference-count":106,"publisher":"Georg Thieme Verlag KG","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hamostaseologie"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs) are acquired clonal disorders of hematopoiesis that typically cause thromboembolic and hemorrhagic complications. These include an increased risk of both arterial and venous thromboembolic events as well as a heightened bleeding tendency. Venous thromboembolic events frequently manifest at atypical sites and characteristically present as splanchnic vein thrombosis. A common cause of the elevated bleeding risk is acquired von Willebrand syndrome. Clinical indicators of an underlying MPN include thromboembolic events of unclear etiology or occurring at atypical sites, as well as acquired cutaneous or mucocutaneous bleeding tendencies. A hallmark of MPN in peripheral blood counts is hyperproliferation. Further diagnostic evaluation includes testing for the three major driver mutations (JAK2, CALR, MPL) and bone marrow biopsy. Management of thromboembolic event requires cytoreductive therapy and, depending on the site of thrombosis, antiplatelet therapy, and\/or anticoagulation.<\/jats:p>\n                  <jats:p>Our review provides an overview of essential thrombocythemia, polycythemia vera, and primary myelofibrosis, as well as the hemostatic disorders associated with these conditions, focusing on diagnostic approaches and the prophylaxis and management of thromboembolic and bleeding complications.<\/jats:p>","DOI":"10.1055\/a-2882-0640","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T23:10:16Z","timestamp":1781219416000},"source":"Crossref","is-referenced-by-count":0,"title":["Coagulation Disorders in Philadelphia Chromosome-negative Myeloproliferative Neoplasms\u2014A Guide for Specialists in Coagulation Disorders"],"prefix":"10.1055","author":[{"given":"Christina C.","family":"Rolling","sequence":"first","affiliation":[{"name":"University Medical Center Hamburg-Eppendorf, Hamburg, Germany","place":["Hamburg"],"department":["Oncology, Hematology and Bone Marrow Transplantation with the Section of Pneumology"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolin","family":"Trautmann-Grill","sequence":"first","affiliation":[{"name":"Technical University Dresden, Sachsen, Germany","place":["Dresden"],"department":["Department of Hematology and Oncology"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7214-8081","authenticated-orcid":false,"given":"Christina","family":"Hart","sequence":"additional","affiliation":[{"name":"University Hospital Regensburg, Bavaria, Germany","place":["Regensburg"],"department":["Department of Hematology and Oncology"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Tiede","sequence":"additional","affiliation":[{"name":"Hannover Medical School, Lower Saxony, Germany","place":["Hannover"],"department":["Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2026,6,11]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3390\/cells10123551","article-title":"Progression of Myeloproliferative neoplasms (MPN): diagnostic and therapeutic perspectives","author":"J Baumeister","year":"2021","journal-title":"Cells"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1177\/10760296221097969","article-title":"Thrombotic and Hemorrhagic issues associated with Myeloproliferative neoplasms","volume":"28","author":"L Papageorgiou","year":"2022","journal-title":"Clin Appl Thromb Hemost"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1055\/a-2482-3997","article-title":"Thrombosis at unusual sites: focus on Myeloproliferative neoplasms and paroxysmal nocturnal Hemoglobinuria","volume":"45","author":"S Koschmieder","year":"2025","journal-title":"Hamostaseologie"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1002\/ajh.27002","article-title":"Polycythemia vera: 2024 update on diagnosis, risk-stratification, and management","volume":"98","author":"A Tefferi","year":"2023","journal-title":"Am J Hematol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1002\/ajh.27216","article-title":"Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and management","volume":"99","author":"A Tefferi","year":"2024","journal-title":"Am J Hematol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1002\/ajh.26984","article-title":"Myelodysplastic syndromes: 2023 update on diagnosis, risk-stratification, and management","volume":"98","author":"G Garcia-Manero","year":"2023","journal-title":"Am J Hematol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1002\/ajh.26821","article-title":"The international consensus classification of myeloid neoplasms and acute leukemias: Myeloproliferative neoplasms","volume":"98","author":"J Thiele","year":"2023","journal-title":"Am J Hematol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International consensus classification of myeloid neoplasms and acute Leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"D A Arber","year":"2022","journal-title":"Blood"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization classification of Haematolymphoid tumours: myeloid and Histiocytic\/dendritic neoplasms","volume":"36","author":"J D Khoury","year":"2022","journal-title":"Leukemia"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1002\/ajh.27443","article-title":"Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring","volume":"99","author":"E Jabbour","year":"2024","journal-title":"Am J Hematol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1002\/cncr.35559","article-title":"New advances in the role of JAK2 V617F mutation in myeloproliferative neoplasms","volume":"130","author":"Y Zhang","year":"2024","journal-title":"Cancer"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1182\/blood.2022017578","article-title":"Genetic basis and molecular profiling in myeloproliferative neoplasms","volume":"141","author":"D Luque Paz","year":"2023","journal-title":"Blood"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1080\/10428194.2025.2465551","article-title":"CALR-mutated myeloproliferative neoplasms","volume":"66","author":"V Bellani","year":"2025","journal-title":"Leuk Lymphoma"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/bs.ircmb.2021.09.003","article-title":"The MPL mutation","volume":"365","author":"P Guglielmelli","year":"2021","journal-title":"Int Rev Cell Mol Biol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.hoc.2020.12.002","article-title":"Genetics of Myeloproliferative neoplasms","volume":"35","author":"J Szybinski","year":"2021","journal-title":"Hematol Oncol Clin North Am"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1007\/s00277-017-3040-8","article-title":"Thromboses and hemorrhages are common in MPN patients with high JAK2V617F allele burden","volume":"96","author":"I Bertozzi","year":"2017","journal-title":"Ann Hematol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1111\/joim.13019","article-title":"Incidence of myeloproliferative neoplasms \u2013 trends by subgroup and age in a population-based study in Sweden","volume":"287","author":"M Hultcrantz","year":"2020","journal-title":"J Intern Med"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1038\/leu.2013.163","article-title":"Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study","volume":"27","author":"A Tefferi","year":"2013","journal-title":"Leukemia"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41408-023-00972-x","article-title":"One thousand patients with essential thrombocythemia: the Mayo Clinic experience","volume":"14","author":"N Gangat","year":"2024","journal-title":"Blood Cancer J"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"3543","DOI":"10.1007\/s00277-024-05894-7","article-title":"Socio-demographic determinants of myelofibrosis outcomes in an underserved center and the SEER national database","volume":"103","author":"J Yan","year":"2024","journal-title":"Ann Hematol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"2634853520978210","DOI":"10.1177\/2634853520978210","article-title":"The essential Thrombocythemia in 2020: what we know and where we still have to dig deep","volume":"13","author":"V Accurso","year":"2020","journal-title":"Clin Med Insights Blood Disord"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3390\/jcm14051537","article-title":"Management of Bleeding, thrombotic and pregnancy-related complications in women with Myeloproliferative neoplasms: a case-based review focusing on sex-specific challenges","author":"T Chiasakul","year":"2025","journal-title":"J Clin Med"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.1182\/blood-2013-03-460154","article-title":"Myeloproliferative neoplasms and thrombosis","volume":"122","author":"T Barbui","year":"2013","journal-title":"Blood"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/s12885-019-5387-9","article-title":"A systematic review and meta-analysis of the prevalence of thrombosis and bleeding at diagnosis of Philadelphia-negative myeloproliferative neoplasms","volume":"19","author":"T Rungjirajittranon","year":"2019","journal-title":"BMC Cancer"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"317","DOI":"10.7326\/M17-0028","article-title":"Risk for arterial and venous thrombosis in patients with Myeloproliferative neoplasms: a population-based cohort study","volume":"168","author":"M Hultcrantz","year":"2018","journal-title":"Ann Intern Med"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1111\/bjh.19337","article-title":"Thromboembolic events, major bleeding and mortality in essential thrombocythaemia and polycythaemia vera-a matched nationwide population-based study","volume":"204","author":"A Enblom-Larsson","year":"2024","journal-title":"Br J Haematol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"2783","DOI":"10.1182\/bloodadvances.2025016247","article-title":"Thrombosis, major bleeding, and mortality in 1079 patients with myelofibrosis: a matched population-based study","volume":"9","author":"A Enblom Larsson","year":"2025","journal-title":"Blood Adv"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1055\/a-2159-8767","article-title":"Arterial and venous thromboembolic complications in 832 patients with BCR-ABL-negative Myeloproliferative neoplasms","volume":"44","author":"K Wille","year":"2024","journal-title":"Hamostaseologie"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"4921","DOI":"10.1182\/blood-2011-09-376517","article-title":"Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis","volume":"120","author":"J H Smalberg","year":"2012","journal-title":"Blood"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1002\/ajh.25677","article-title":"Splanchnic vein thromboses associated with myeloproliferative neoplasms: an international, retrospective study on 518 cases","volume":"95","author":"E Sant'Antonio","year":"2020","journal-title":"Am J Hematol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"e77","DOI":"10.1161\/STR.0000000000000456","article-title":"Diagnosis and Management of Cerebral Venous Thrombosis: a scientific statement from the American Heart Association","volume":"55","author":"G Saposnik","year":"2024","journal-title":"Stroke"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1200\/JCO.2005.07.062","article-title":"Vascular and neoplastic risk in a large cohort of patients with polycythemia vera","volume":"23","author":"R Marchioli","year":"2005","journal-title":"J Clin Oncol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3390\/ijms23063206","article-title":"Thromboinflammation in Myeloproliferative neoplasms (MPN)-a puzzle still to be solved","author":"V Bhuria","year":"2022","journal-title":"Int J Mol Sci"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1182\/blood-2006-10-048298","article-title":"Increased adhesion to endothelial cells of erythrocytes from patients with polycythemia vera is mediated by laminin alpha5 chain and Lu\/BCAM","volume":"110","author":"M P Wautier","year":"2007","journal-title":"Blood"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.clml.2019.11.010","article-title":"Elevated white blood cell levels and thrombotic events in patients with Polycythemia Vera: a real-world analysis of veterans health administration data","volume":"20","author":"S Parasuraman","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.thromres.2022.01.011","article-title":"JAK2 allele burden is correlated with a risk of venous but not arterial thrombosis","volume":"211","author":"S Soudet","year":"2022","journal-title":"Thromb Res"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1007\/s00277-024-05754-4","article-title":"Association of JAK2V617F allele burden and clinical correlates in polycythemia vera: a systematic review and meta-analysis","volume":"103","author":"C C Chen","year":"2024","journal-title":"Ann Hematol"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1038\/sj.leu.2404854","article-title":"Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden","volume":"21","author":"A M Vannucchi","year":"2007","journal-title":"Leukemia"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1002\/ajh.23676","article-title":"JAK2V617F monitoring in polycythemia vera and essential thrombocythemia: clinical usefulness for predicting myelofibrotic transformation and thrombotic events","volume":"89","author":"A Alvarez-Larran","year":"2014","journal-title":"Am J Hematol"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"2813","DOI":"10.3324\/haematol.2021.278499","article-title":"The possible role of mutated endothelial cells in myeloproliferative neoplasms","volume":"106","author":"M Farina","year":"2021","journal-title":"Haematologica"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1055\/a-2239-9265","article-title":"DNMT3A\/TET2\/ASXL1 mutations are an age-independent thrombotic risk factor in Polycythemia Vera patients: an observational study","volume":"124","author":"A Segura-Diaz","year":"2024","journal-title":"Thromb Haemost"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1111\/jth.12265","article-title":"Thrombotic complications of myeloproliferative neoplasms: risk assessment and risk-guided management","volume":"11","author":"A Casini","year":"2013","journal-title":"J Thromb Haemost"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1002\/ajh.21338","article-title":"Platelet turnover, coagulation factors, and soluble markers of platelet and endothelial activation in essential thrombocythemia: relationship with thrombosis occurrence and JAK2 V617F allele burden","volume":"84","author":"E Arellano-Rodrigo","year":"2009","journal-title":"Am J Hematol"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"S71","DOI":"10.1016\/S0049-3848(16)30102-5","article-title":"Molecular biomarkers of thrombosis in myeloproliferative neoplasms","volume":"140","author":"T Barbui","year":"2016","journal-title":"Thromb Res"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1055\/s-0040-1720979","article-title":"Hemorrhage in essential Thrombocythemia or Polycythemia Vera: epidemiology, location, risk factors, and lessons learned from the literature","volume":"121","author":"C Nicol","year":"2021","journal-title":"Thromb Haemost"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1111\/ejh.13721","article-title":"Bleeding complications in bcr-abl-negative myeloproliferative neoplasms (MPN): a retrospective single-center study of 829 MPN patients","volume":"108","author":"K Wille","year":"2022","journal-title":"Eur J Haematol"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13045-016-0242-9","article-title":"Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry","volume":"9","author":"A Kaifie","year":"2016","journal-title":"J Hematol Oncol"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s11899-017-0400-3","article-title":"Risk factors for and management of MPN-associated bleeding and thrombosis","volume":"12","author":"K Martin","year":"2017","journal-title":"Curr Hematol Malig Rep"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"51","DOI":"10.3324\/haematol.2017.174672","article-title":"Treatment of essential thrombocythemia in Europe: a prospective long-term observational study of 3649 high-risk patients in the evaluation of Anagrelide efficacy and long-term safety study","volume":"103","author":"G Birgegard","year":"2018","journal-title":"Haematologica"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/hae.14995","volume":"30","author":"A Tiede","year":"2024","journal-title":"Haemophilia"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.3324\/haematol.2020.255117","article-title":"Acquired von Willebrand syndrome: focused for hematologists","volume":"105","author":"M Franchini","year":"2020","journal-title":"Haematologica"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ejim.2016.11.011","article-title":"Factors related to the development of acquired von Willebrand syndrome in patients with essential thrombocythemia and polycythemia vera","volume":"41","author":"A Rottenstreich","year":"2017","journal-title":"Eur J Intern Med"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"914","DOI":"10.20452\/pamw.3211","article-title":"Prevalence of acquired von Willebrand syndrome during essential thrombocythemia: a retrospective analysis of 170 consecutive patients","volume":"125","author":"A Mital","year":"2015","journal-title":"Pol Arch Med Wewn"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.thromres.2022.08.002","article-title":"Evaluation of different diagnostic tools for detection of acquired von Willebrand syndrome in patients with polycythemia vera or essential thrombocythemia","volume":"218","author":"S Janjetovic","year":"2022","journal-title":"Thromb Res"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1046\/j.1365-2141.1996.d01-1729.x","article-title":"The reduction of large von Willebrand factor multimers in plasma in essential thrombocythaemia is related to the platelet count","volume":"93","author":"P J van Genderen","year":"1996","journal-title":"Br J Haematol"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"102954","DOI":"10.1016\/j.rpth.2025.102954","article-title":"Thrombocytosis and bleeding in myeloproliferative neoplasms: exploring clinical diversity and risk of acquired von Willebrand syndrome-insights from a UK center","volume":"9","author":"G Simini","year":"2025","journal-title":"Res Pract Thromb Haemost"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1111\/bjh.18322","article-title":"Practical management of the haemorrhagic complications of myeloproliferative neoplasms","volume":"199","author":"E Jones","year":"2022","journal-title":"Br J Haematol"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"2751","DOI":"10.2169\/internalmedicine.4912-20","article-title":"Acquired Gray platelet syndrome associated with primary Myelofibrosis","volume":"59","author":"K Ido","year":"2020","journal-title":"Intern Med"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1002\/ajh.26857","article-title":"Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management","volume":"98","author":"A Tefferi","year":"2023","journal-title":"Am J Hematol"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1055\/s-2006-947866","article-title":"Laboratory testing for von Willebrand disease: contribution of multimer analysis to diagnosis and classification","volume":"32","author":"U Budde","year":"2006","journal-title":"Semin Thromb Hemost"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1111\/j.1538-7836.2008.02909.x","article-title":"Diagnostic workup of patients with acquired von Willebrand syndrome: a retrospective single-Centre cohort study","volume":"6","author":"A Tiede","year":"2008","journal-title":"J Thromb Haemost"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1016\/S0049-3848(13)70003-3","article-title":"Diagnosis and treatment of acquired von Willebrand syndrome","volume":"130","author":"A Tiede","year":"2012","journal-title":"Thromb Res"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.thromres.2019.06.009","article-title":"Acquired platelet function disorders","volume":"196","author":"Y Brennan","year":"2020","journal-title":"Thromb Res"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"5128","DOI":"10.1182\/blood-2012-07-444067","article-title":"Development and validation of an international prognostic score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis)","volume":"120","author":"T Barbui","year":"2012","journal-title":"Blood"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"e369","DOI":"10.1038\/bcj.2015.94","article-title":"Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia","volume":"5","author":"T Barbui","year":"2015","journal-title":"Blood Cancer J"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"e936","DOI":"10.1097\/HS9.0000000000000936","article-title":"Application of IPSET-thrombosis in 1366 patients prospectively followed from the Spanish registry of essential Thrombocythemia","volume":"7","author":"A Alvarez-Larran","year":"2023","journal-title":"Hema"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41408-020-0289-2","article-title":"Validation of the IPSET score for thrombosis in patients with prefibrotic myelofibrosis","volume":"10","author":"P Guglielmelli","year":"2020","journal-title":"Blood Cancer J"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1056\/NEJMc1301262","article-title":"Treatment target in polycythemia vera","volume":"368","author":"R Marchioli","year":"2013","journal-title":"N Engl J Med"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"2681","DOI":"10.1182\/bloodadvances.2018021436","article-title":"The impact of phlebotomy and hydroxyurea on survival and risk of thrombosis among older patients with polycythemia vera","volume":"2","author":"N A Podoltsev","year":"2018","journal-title":"Blood Adv"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1111\/j.1365-2141.2009.08019.x","article-title":"A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process","volume":"148","author":"G Barosi","year":"2010","journal-title":"Br J Haematol"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1056\/NEJMoa035572","article-title":"Efficacy and safety of low-dose aspirin in polycythemia vera","volume":"350","author":"R Landolfi","year":"2004","journal-title":"N Engl J Med"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1182\/blood.2019004596","article-title":"A randomized double-blind trial of 3 aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia","volume":"136","author":"B Rocca","year":"2020","journal-title":"Blood"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.3324\/haematol.2022.281388","article-title":"Aspirin in essential thrombocythemia. For whom? What formulation? What regimen?","volume":"108","author":"M Cattaneo","year":"2023","journal-title":"Haematologica"},{"key":"ref74","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/S1470-2045(16)30558-7","article-title":"Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study","volume":"18","author":"F Passamonti","year":"2017","journal-title":"Lancet Oncol"},{"key":"ref76","doi-asserted-by":"publisher","first-page":"372","DOI":"10.3324\/haematol.12053","article-title":"Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments","volume":"93","author":"V De Stefano","year":"2008","journal-title":"Haematologica"},{"key":"ref77","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41408-023-00968-7","article-title":"One thousand patients with essential thrombocythemia: the Florence-CRIMM experience","volume":"14","author":"G G Loscocco","year":"2024","journal-title":"Blood Cancer J"},{"key":"ref78","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1182\/blood-2010-01-263319","article-title":"Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia","volume":"116","author":"A Alvarez-Larran","year":"2010","journal-title":"Blood"},{"key":"ref80","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1055\/s-0040-1701474","article-title":"How I manage thrombotic\/thromboembolic complications in Myeloproliferative neoplasms","volume":"40","author":"S Koschmieder","year":"2020","journal-title":"Hamostaseologie"},{"key":"ref81","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1056\/NEJM199504273321704","article-title":"Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis","volume":"332","author":"S Cortelazzo","year":"1995","journal-title":"N Engl J Med"},{"key":"ref82","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1182\/blood-2010-03-272179","article-title":"Hydroxyurea in essential thrombocythemia: rate and clinical relevance of responses by European LeukemiaNet criteria","volume":"116","author":"A Carobbio","year":"2010","journal-title":"Blood"},{"key":"ref83","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1182\/bloodadvances.2022008259","article-title":"Second malignancies among older patients with classical myeloproliferative neoplasms treated with hydroxyurea","volume":"7","author":"R Wang","year":"2023","journal-title":"Blood Adv"},{"key":"ref84","volume-title":"Essentielle (Oder prim\u00e4re) Thrombozyth\u00e4mie (ET)","author":"G M Petrides PEB","year":"2023"},{"key":"ref85","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa043800","article-title":"Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia","volume":"353","author":"C N Harrison","year":"2005","journal-title":"N Engl J Med"},{"key":"ref86","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/ajh.25294","article-title":"Decreased survival and increased rate of fibrotic progression in essential thrombocythemia chronicled after the FDA approval date of anagrelide","volume":"94","author":"A Tefferi","year":"2019","journal-title":"Am J Hematol"},{"key":"ref87","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1007\/s00277-017-3099-2","article-title":"The underappreciated risk of thrombosis and bleeding in patients with myelofibrosis: a review","volume":"96","author":"D Kc","year":"2017","journal-title":"Ann Hematol"},{"key":"ref88","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1038\/s41375-022-01673-3","article-title":"Prediction of thrombosis in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study on 1258 patients","volume":"36","author":"B Mora","year":"2022","journal-title":"Leukemia"},{"key":"ref89","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1182\/blood.2024025627","article-title":"How I approach the treatment of thrombotic complications in patients with myeloproliferative neoplasms","volume":"145","author":"A Guy","year":"2025","journal-title":"Blood"},{"key":"ref90","doi-asserted-by":"publisher","first-page":"59","DOI":"10.3390\/medicina59071300","article-title":"Essential Thrombocythemia and ischemic stroke: a case series of five JAK2-positive patients","author":"B K Kim","year":"2023","journal-title":"Medicina"},{"key":"ref91","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1182\/bloodadvances.2020003628","article-title":"A systematic review of antithrombotic treatment of venous thromboembolism in patients with myeloproliferative neoplasms","volume":"5","author":"E N Hamulyak","year":"2021","journal-title":"Blood Adv"},{"key":"ref92","doi-asserted-by":"publisher","first-page":"4693","DOI":"10.1182\/bloodadvances.2020001830","article-title":"American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism","volume":"4","author":"T L Ortel","year":"2020","journal-title":"Blood Adv"},{"key":"ref93","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.annonc.2022.12.014","article-title":"Venous thromboembolism in cancer patients: ESMO clinical practice guideline","volume":"34","author":"A Falanga","year":"2023","journal-title":"Ann Oncol"},{"key":"ref94","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1038\/leu.2016.85","article-title":"High rate of recurrent venous thromboembolism in patients with myeloproliferative neoplasms and effect of prophylaxis with vitamin K antagonists","volume":"30","author":"V De Stefano","year":"2016","journal-title":"Leukemia"},{"key":"ref95","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1111\/jth.14836","article-title":"Anticoagulant therapy for splanchnic vein thrombosis: ISTH SSC subcommittee control of anticoagulation","volume":"18","author":"M Di Nisio","year":"2020","journal-title":"J Thromb Haemost"},{"key":"ref96","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1016\/j.cgh.2008.07.031","article-title":"Portal hypertension-related complications after acute portal vein thrombosis: impact of early anticoagulation","volume":"6","author":"J Turnes","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref97","doi-asserted-by":"publisher","first-page":"3479","DOI":"10.1016\/j.jtha.2024.06.029","article-title":"Anticoagulation for splanchnic vein thrombosis in myeloproliferative neoplasms: a systematic review and meta-analysis","volume":"22","author":"P Chrysafi","year":"2024","journal-title":"J Thromb Haemost"},{"key":"ref98","doi-asserted-by":"publisher","first-page":"e493","DOI":"10.1038\/bcj.2016.103","article-title":"Splanchnic vein thrombosis in myeloproliferative neoplasms: risk factors for recurrences in a cohort of 181 patients","volume":"6","author":"V De Stefano","year":"2016","journal-title":"Blood Cancer J"},{"key":"ref99","doi-asserted-by":"publisher","first-page":"4516","DOI":"10.1182\/bloodadvances.2022007961","article-title":"Anticoagulant therapy for splanchnic vein thrombosis: an individual patient data meta-analysis","volume":"6","author":"M Candeloro","year":"2022","journal-title":"Blood Adv"},{"key":"ref100","doi-asserted-by":"publisher","first-page":"EVIDoa2200104","DOI":"10.1056\/EVIDoa2200104","article-title":"Rivaroxaban prophylaxis in noncirrhotic portal vein thrombosis","volume":"1","author":"A Plessier","year":"2022","journal-title":"NEJM Evid"},{"key":"ref102","doi-asserted-by":"publisher","first-page":"2989","DOI":"10.1038\/s41375-021-01279-1","article-title":"Direct oral anticoagulants for myeloproliferative neoplasms: results from an international study on 442 patients","volume":"35","author":"T Barbui","year":"2021","journal-title":"Leukemia"},{"key":"ref103","doi-asserted-by":"publisher","first-page":"E329","DOI":"10.1002\/ajh.25990","article-title":"A multicenter real-life study on anticoagulant treatment with direct oral anticoagulants in patients with Ph-negative myeloproliferative neoplasms","volume":"95","author":"A Serrao","year":"2020","journal-title":"Am J Hematol"},{"key":"ref104","doi-asserted-by":"publisher","first-page":"E61","DOI":"10.1002\/ajh.24993","article-title":"Splanchnic vein thrombosis in patients with myeloproliferative neoplasms: the Mayo clinic experience with 84 consecutive cases","volume":"93","author":"S Lavu","year":"2018","journal-title":"Am J Hematol"},{"key":"ref105","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1161\/STROKEAHA.121.037541","article-title":"Direct Oral anticoagulants versus warfarin in the treatment of cerebral venous thrombosis (ACTION-CVT): a Multicenter international study","volume":"53","author":"S Yaghi","year":"2022","journal-title":"Stroke"},{"key":"ref106","doi-asserted-by":"publisher","first-page":"1404099","DOI":"10.3389\/fneur.2024.1404099","article-title":"Efficacy and safety of Apixaban in the treatment of cerebral venous sinus thrombosis: a multi-center study","volume":"15","author":"N Simaan","year":"2024","journal-title":"Front Neurol"},{"key":"ref107","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1182\/blood.V68.6.1213.1213","article-title":"Subunit composition of plasma von Willebrand factor in patients with the myeloproliferative syndrome","volume":"68","author":"U Budde","year":"1986","journal-title":"Blood"},{"key":"ref108","doi-asserted-by":"publisher","first-page":"6777","DOI":"10.1182\/blood-2010-11-297580","article-title":"How I treat the acquired von Willebrand syndrome","volume":"117","author":"A Tiede","year":"2011","journal-title":"Blood"},{"key":"ref109","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1267\/hamo04010050","volume":"24","author":"A B Federici","year":"2004","journal-title":"Hamostaseologie"}],"container-title":["H\u00e4mostaseologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2882-0640.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T23:10:18Z","timestamp":1781219418000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2882-0640"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,11]]},"references-count":106,"URL":"https:\/\/doi.org\/10.1055\/a-2882-0640","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0720-9355","2567-5761"],"issn-type":[{"value":"0720-9355","type":"print"},{"value":"2567-5761","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,11]]}}}